EFTR

Effector Therapeutics Inc. (EFTR) | Rumor.io

Effector Therapeutics

EFTR

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)0%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-35.8M

Social

What share of all stock conversation is about EFTR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Dec 20

eFFECTOR Therapeutics, Inc. (EFTR) is associated with VATN systems, a company producing the Skelmir S6 Compact Modular Underwater Effector.
The Skelmir S6 is an autonomous system designed for naval operations, offering a solution to attrit threats and deploy sensors and decoys.
VATN's mission software enables a single user to plan and monitor hundreds of units, acting as a force multiplier.

Generated by AI

Sentiment

Of the messages about EFTR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	9.09% -56.43
Bearish	—	—	—	90.91% +56.43

Bullish· Jun 25

$EFTR has a market cap of $1.4m, making it potentially vulnerable to a buyout by Pfizer, which holds shares and stands to gain up to $500m in royalty payments.
The stock's low float of 4.7 million shares and high trading volume over the last 2 days suggest a significant buy order or accumulation by a large investor.
With a tight range and limited chatter about the stock, it appears that a deep-pocketed buyer is accumulating shares in anticipation of a potential price spike before the stock is delisted.

Bearish· Jun 24

eFFECTOR Therapeutics, Inc. ($EFTR) is winding down operations and seeking strategic alternatives, which may lead to delisting from Nasdaq.
The company has laid off staff and is expected to be delisted, with a market capitalization of $1.4 million and a float of approximately $4 million.
The stock has experienced a significant decline, plummeting by nearly 75% in pre-market trading after the company announced its plans to wind down operations.

Generated by AI

Topics

Of the messages about EFTR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Analysts· Jan 25

JMP Securities lowered eFFECTOR Therapeutics' price target to $8 from $33, maintaining a Market Outperform rating.
Stifel Nicolaus downgraded eFFECTOR Therapeutics to Hold from Buy and lowered the price target to $6.2 from $20.
Credit Suisse maintained an Outperform rating on eFFECTOR Therapeutics with a lowered price target of $16 from $20.

Announcements· Dec 20

eFFECTOR Therapeutics, Inc. (EFTR) CEO is associated with VATN Systems, a company developing autonomous underwater systems for naval operations.
VATN's Skelmir S6 Compact Modular Underwater Effector is designed for rapid manufacturing and deployment of sensors and decoys on a large scale.
VATN's mission software enables a single user to plan and monitor hundreds of units, providing a force multiplier for naval operations.

Technical Analysis· May 26

$EFTR is at resistance, with traders advised to manage their trades.
The stock has formed a cup and handle pattern, with a possible entry and exit on the 15-minute chart.
A technical analysis of $EFTR's MACD and RSI indicates hidden bearish divergence, but the trend is still expected to continue upward.

Generated by AI

Community

Of the messages about EFTR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	10%	1.47%	19%
Newcomers	100%	90%	98.53%	81%

Regulars· Jun 24

eFFECTOR Therapeutics, Inc. ($EFTR) is winding down its operations and seeking strategic alternatives for its development programs, with shares plummeting nearly 75% in value.
The company's decision to shut down operations and potentially delist from Nasdaq is a significant development, with implications for its development programs, including a collaboration with Pfizer.
The stock's significant price drop, with a nearly 75% decline, suggests that investors are losing confidence in the company's prospects, particularly given the timing of the announcement, which coincides with an ongoing clinical trial.

Newcomers· Jun 25

$EFTR is being watched for a potential dead-cat bounce.
The delisting date for $EFTR is July 3, and some traders are keeping an eye on it.
The stock has seen a significant pop in after-hours trading, with some traders achieving gains of 30-50% or more.

Generated by AI

Mr. Smither brings extensive public company board and audit committee experience in the biotechnology sectorSAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the appointment of John W. Smither to its Board of Directors as an independent director and as Chair of the Audit Committee. “We

2mo agoYahoo Finance

Also Discussed

Investors talking about EFTR also mention

#	Name	Attention
1	Better Therapeutics, Inc.BTTX	0%new
2	PDS Biotechnology CorporationPDSB	0%-0.01
3	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
4	HOOK - HOOKIPA Pharma Inc.	——
5	ACHL - Achilles Therapeutics plc	——
6	X4 Pharmaceuticals, Inc.XFOR	0%0
7	Surrozen, Inc.SRZN	0%0
8	DAWN - Day One Biopharmaceuticals, Inc.	——
9	GRTX - Galera Therapeutics, Inc.	——
10	NARI - Inari Medical, Inc.	——

Effector Therapeutics Inc.

Healthcare
Biotechnology

Effector Therapeutics Inc. is a biopharmaceutical company focused on the development of selective translation regulators for the treatment of cancer. Translation regulation is a novel approach in oncology that targets the protein synthesis process in cells, seeking to disrupt the production of proteins essential for the growth and survival of cancer cells. By targeting this mechanism, Effector Therapeutics aims to provide innovative therapies that can complement existing treatment regimens. This approach has the potential to impact a wide range of cancers, offering new hope for patients with tumors that are resistant to traditional therapies. Founded to harness the power of translational control, Effector Therapeutics exemplifies the burgeoning field of oncology biopharmaceuticals, combining scientific expertise with cutting-edge technologies to address unmet medical needs. Operating within the dynamic and high-stakes biotechnology industry, the company contributes to ongoing advancements in cancer treatment.

Website

Location

142 North Cedros Avenue

Solana Beach, CA, 92075

United States

Social

What share of all stock conversation is about EFTR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Dec 20

eFFECTOR Therapeutics, Inc. (EFTR) is associated with VATN systems, a company producing the Skelmir S6 Compact Modular Underwater Effector.
The Skelmir S6 is an autonomous system designed for naval operations, offering a solution to attrit threats and deploy sensors and decoys.
VATN's mission software enables a single user to plan and monitor hundreds of units, acting as a force multiplier.

Generated by AI

Sentiment

Of the messages about EFTR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	9.09% -56.43
Bearish	—	—	—	90.91% +56.43

Bullish· Jun 25

$EFTR has a market cap of $1.4m, making it potentially vulnerable to a buyout by Pfizer, which holds shares and stands to gain up to $500m in royalty payments.
The stock's low float of 4.7 million shares and high trading volume over the last 2 days suggest a significant buy order or accumulation by a large investor.
With a tight range and limited chatter about the stock, it appears that a deep-pocketed buyer is accumulating shares in anticipation of a potential price spike before the stock is delisted.

Bearish· Jun 24

eFFECTOR Therapeutics, Inc. ($EFTR) is winding down operations and seeking strategic alternatives, which may lead to delisting from Nasdaq.
The company has laid off staff and is expected to be delisted, with a market capitalization of $1.4 million and a float of approximately $4 million.
The stock has experienced a significant decline, plummeting by nearly 75% in pre-market trading after the company announced its plans to wind down operations.

Generated by AI

Topics

Of the messages about EFTR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Analysts· Jan 25

JMP Securities lowered eFFECTOR Therapeutics' price target to $8 from $33, maintaining a Market Outperform rating.
Stifel Nicolaus downgraded eFFECTOR Therapeutics to Hold from Buy and lowered the price target to $6.2 from $20.
Credit Suisse maintained an Outperform rating on eFFECTOR Therapeutics with a lowered price target of $16 from $20.

Announcements· Dec 20

eFFECTOR Therapeutics, Inc. (EFTR) CEO is associated with VATN Systems, a company developing autonomous underwater systems for naval operations.
VATN's Skelmir S6 Compact Modular Underwater Effector is designed for rapid manufacturing and deployment of sensors and decoys on a large scale.
VATN's mission software enables a single user to plan and monitor hundreds of units, providing a force multiplier for naval operations.

Technical Analysis· May 26

$EFTR is at resistance, with traders advised to manage their trades.
The stock has formed a cup and handle pattern, with a possible entry and exit on the 15-minute chart.
A technical analysis of $EFTR's MACD and RSI indicates hidden bearish divergence, but the trend is still expected to continue upward.

Generated by AI

Community

Of the messages about EFTR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	10%	1.47%	19%
Newcomers	100%	90%	98.53%	81%

Regulars· Jun 24

eFFECTOR Therapeutics, Inc. ($EFTR) is winding down its operations and seeking strategic alternatives for its development programs, with shares plummeting nearly 75% in value.
The company's decision to shut down operations and potentially delist from Nasdaq is a significant development, with implications for its development programs, including a collaboration with Pfizer.
The stock's significant price drop, with a nearly 75% decline, suggests that investors are losing confidence in the company's prospects, particularly given the timing of the announcement, which coincides with an ongoing clinical trial.

Newcomers· Jun 25

$EFTR is being watched for a potential dead-cat bounce.
The delisting date for $EFTR is July 3, and some traders are keeping an eye on it.
The stock has seen a significant pop in after-hours trading, with some traders achieving gains of 30-50% or more.

Generated by AI

Effector Therapeutics

Social

Dec 20

Sentiment

Bullish· Jun 25

Bearish· Jun 24

Topics

Analysts· Jan 25

Announcements· Dec 20

Technical Analysis· May 26

Community

Regulars· Jun 24

Newcomers· Jun 25

News

Attovia Therapeutics Appoints John W. Smither to Board of Directors

Also Discussed

Effector Therapeutics Inc.

Company Information

Location

Social

Dec 20

Sentiment

Bullish· Jun 25

Bearish· Jun 24

Topics

Analysts· Jan 25

Announcements· Dec 20

Technical Analysis· May 26

Community

Regulars· Jun 24

Newcomers· Jun 25

News

Attovia Therapeutics Appoints John W. Smither to Board of Directors

Also Discussed